AI Article Synopsis
- Transgene SA is working on TG-1042, a modified adenovirus designed to deliver the IFNgamma gene for treating specific types of lymphoma (CTCL and CBCL).
- A phase I/II clinical trial for this treatment has just been completed.
- In November 2006, Transgene began a phase II clinical trial focusing on CBCL.
Article Abstract
Transgene SA is developing TG-1042, a replication-deficient adenovirus type 5 that carries the IFNgamma gene, for the potential treatment of cutaneous T-cell and B-cell lymphoma (CTCL and CBCL, respectively). A phase I/II clinical trial in CTCL and CBCL was recently completed, and in November 2006 Transgene initiated a phase II clinical trial in CBCL.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
ifngamma gene
8
ctcl cbcl
8
clinical trial
8
drug evaluation
4
evaluation tg-1042
4
tg-1042 adenovirus-mediated
4
adenovirus-mediated ifngamma
4
gene delivery
4
delivery intratumoral
4
intratumoral therapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!